Follicular helper-T cells restore CD8
Adoptive Transfer
Animals
Antineoplastic Agents, Immunological
/ administration & dosage
Brain Neoplasms
/ immunology
Breast Neoplasms
/ genetics
CD8-Positive T-Lymphocytes
/ metabolism
Cell Line, Tumor
Chemokine CXCL13
/ genetics
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ drug effects
Glioblastoma
/ genetics
Humans
Immune Checkpoint Inhibitors
/ administration & dosage
Interleukins
/ genetics
Mice
T Follicular Helper Cells
/ immunology
Treatment Outcome
Xenograft Model Antitumor Assays
CD8-positive T-lymphocytes
immunotherapy
programmed cell death 1 receptor
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
accepted:
20
04
2021
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
21
12
2021
Statut:
ppublish
Résumé
T follicular helper cells (Tfh) are essential to shape B cell response during germinal center formation. Tfh accumulation has been reported in various human cancers, with positive or negative prognostic roles. However, the mechanisms explaining the accumulation of Tfh and their role in cancer remain obscure. In vitro differentiated and mouse cell sorted Tfh phenotype was evaluated by flow cytometry and quantitative PCR (qPCR). Antitumor effect of Tfh was evaluated by adoptive transfer in different tumor-bearing mice models. The involvement of immune cells, cytokines and chemokines was evaluated, using depleting antibodies. Chemokines and cytokines expression and production were evaluated by qPCR and ELISA. In human, the impact of immune cells and chemokines on survival was evaluated by analyzing transcriptomic data from public databases and from our own patient cohorts. In this study, we show that Tfh exert an antitumor immune effect in a CD8 This study provides evidence that CD8
Sections du résumé
BACKGROUND
T follicular helper cells (Tfh) are essential to shape B cell response during germinal center formation. Tfh accumulation has been reported in various human cancers, with positive or negative prognostic roles. However, the mechanisms explaining the accumulation of Tfh and their role in cancer remain obscure.
METHODS
In vitro differentiated and mouse cell sorted Tfh phenotype was evaluated by flow cytometry and quantitative PCR (qPCR). Antitumor effect of Tfh was evaluated by adoptive transfer in different tumor-bearing mice models. The involvement of immune cells, cytokines and chemokines was evaluated, using depleting antibodies. Chemokines and cytokines expression and production were evaluated by qPCR and ELISA. In human, the impact of immune cells and chemokines on survival was evaluated by analyzing transcriptomic data from public databases and from our own patient cohorts.
RESULTS
In this study, we show that Tfh exert an antitumor immune effect in a CD8
CONCLUSION
This study provides evidence that CD8
Identifiants
pubmed: 34103351
pii: jitc-2020-002157
doi: 10.1136/jitc-2020-002157
pmc: PMC8190041
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
CXCL13 protein, human
0
Chemokine CXCL13
0
Immune Checkpoint Inhibitors
0
Interleukins
0
interleukin-21
MKM3CA6LT1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: FG received speaker honoraria from Lilly, Sanofi, BMS, Astra Zeneca and Amgen, received funding for clinical trials from Astra Zeneca, received travel grants from Roche France, Amgen and Servier, and is an advisory board member for Merck Serano, Amgen, Roche France and Sanofi.
Références
J Immunol. 2007 Oct 15;179(8):5099-108
pubmed: 17911595
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):6047-6055
pubmed: 32123114
Science. 2009 Jun 19;324(5934):1572-6
pubmed: 19443735
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Sci Immunol. 2016 Jul 14;1(1):aaf6925
pubmed: 28783673
Oncoimmunology. 2013 Oct 1;2(10):e26066
pubmed: 24244900
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Sci Rep. 2020 Jan 20;10(1):643
pubmed: 31959763
Cancers (Basel). 2014 Apr 23;6(2):969-97
pubmed: 24762633
J Immunol. 2010 Jan 1;184(1):114-26
pubmed: 19949086
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Immunity. 2009 Aug 21;31(2):309-20
pubmed: 19664943
Front Immunol. 2019 Nov 15;10:2689
pubmed: 31803194
Microbes Infect. 2010 Dec;12(14-15):1111-9
pubmed: 20817119
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
PLoS Pathog. 2013;9(6):e1003422
pubmed: 23818845
Life Sci. 2019 Jun 15;227:175-186
pubmed: 31026453
Immunity. 2019 Dec 17;51(6):1043-1058.e4
pubmed: 31810882
Trends Cancer. 2017 Jan;3(1):56-71
pubmed: 28718426
Trends Immunol. 2014 Nov;35(11):571-80
pubmed: 25443495
J Immunother Cancer. 2017 Feb 21;5:18
pubmed: 28239471
Immunol Rev. 2019 Mar;288(1):28-36
pubmed: 30874359
Science. 2009 Jun 19;324(5934):1569-72
pubmed: 19423777
Science. 2009 Jun 19;324(5934):1576-80
pubmed: 19478140
Annu Rev Immunol. 2016 May 20;34:335-68
pubmed: 26907215
Blood. 2007 May 15;109(10):4135-42
pubmed: 17234735
Annu Rev Immunol. 2011;29:621-63
pubmed: 21314428
Clin Cancer Res. 2016 May 1;22(9):2207-16
pubmed: 26660518
Nat Immunol. 2016 Oct;17(10):1197-1205
pubmed: 27573866
Cancer Immunol Res. 2019 May;7(5):784-796
pubmed: 30872264
Nat Rev Drug Discov. 2014 May;13(5):379-95
pubmed: 24751819
Immunity. 2019 Dec 17;51(6):1028-1042.e4
pubmed: 31810883
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
J Immunol. 2007 Sep 1;179(5):2880-8
pubmed: 17709502
J Virol. 2011 Mar;85(5):2316-24
pubmed: 21159862
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Cancer Immunol Res. 2020 May;8(5):698-709
pubmed: 32122993
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
J Immunother Cancer. 2018 Jun 4;6(1):47
pubmed: 29866156
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
J Clin Invest. 2011 Mar;121(3):1154-62
pubmed: 21393863
Int Immunopharmacol. 2016 Dec;41:1-7
pubmed: 27788370
Immunol Lett. 2016 Jun;174:23-7
pubmed: 27085379
Science. 2016 Dec 2;354(6316):1165-1169
pubmed: 27789799
Immunol Cell Biol. 2015 May-Jun;93(5):486-99
pubmed: 25533286
Front Immunol. 2016 Oct 03;7:407
pubmed: 27752258
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Appl Biochem Biotechnol. 2018 Jun;185(2):484-493
pubmed: 29192391
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
J Immunol. 2004 Jul 1;173(1):68-78
pubmed: 15210760
Cancer Res. 2017 Jul 1;77(13):3540-3550
pubmed: 28487385
Cell Rep. 2015 Nov 10;13(6):1118-1124
pubmed: 26527008
Cancer Cell. 2018 Jun 11;33(6):1017-1032.e7
pubmed: 29894689